Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02814019 · ClinicalTrials.gov registry record · Phase 3
A Phase III Double-blind Study With Idebenone in Patients With Duchenne Muscular Dystrophy (DMD) Taking Glucocorticoid Steroids
A Phase 3 study, sponsored by Santhera Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 255
- Enrollment target
NCT02814019 is a Phase 3 study that was terminated before completion, run by Santhera Pharmaceuticals. The registered enrollment target is 255 participants.
The verdict
NCT02814019, a Phase 3 study, was terminated before completion, sponsored by Santhera Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 255 participants
- Enrollment target
Study Summary
The purpose of the study is to assess the efficacy of idebenone in delaying the loss of respiratory function in patients with DMD receiving concomitant glucocorticoid steroids
Interventions
- DRUG placebo
- DRUG Idebenone 150 mg film-coated tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 255 participants |
| Start Date | 2016-09 |
| Est. Completion | 2020-12-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02814019
The ClinicalTrials.gov registry entry for NCT02814019 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 255 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Santhera Pharmaceuticals, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT02814019 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02814019 about?
NCT02814019 is a clinical study titled "A Phase III Double-blind Study With Idebenone in Patients With Duchenne Muscular Dystrophy (DMD) Taking Glucocorticoid Steroids". The purpose of the study is to assess the efficacy of idebenone in delaying the loss of respiratory function in patients with DMD receiving concomitant glucocorticoid steroids
What is the current status of trial NCT02814019?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 255 participants. The study started on 2016-09. Estimated completion is 2020-12-01.
What interventions are being tested in trial NCT02814019?
The interventions under investigation include: placebo (DRUG), Idebenone 150 mg film-coated tablets (DRUG).
Who is sponsoring clinical trial NCT02814019?
This trial is sponsored by Santhera Pharmaceuticals, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.